$612 | SAVE $83 | Single User
$1228 | SAVE $167 | Global License

Physician Views: Expanded access in cancer – how are oncologists utilising this opportunity?
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 28 Apr 2014 | 117 | In Stock
Related Topics: FDA , Healthcare

Introduction

Scope



According to analysts at Barclays, oncology continues to attract around one-third of pharma's total R&D investment. This trend is driven by a number of factors, not least the commercial opportunity afforded to a disease area where unmet need remains high. However, in addition, regulatory and healthcare provision architecture around cancer products affords developers both the opportunity to secure expedited approval and access a larger number of patients prior to regulatory clearance or launch.


Last month, the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) announced the soon-to-launch 'Early Access to Medicine Scheme' (EAMS), a system which has drawn comparison to the FDA's 'breakthrough therapy' designation and which can be expected to attract its fair share of applications from cancer drug developers - ViewPoints: The UK's 'early access to medicine scheme' – close cousin or distant relative to FDA breakthrough status?


Such a framework also includes expanded access – or named patient – programmes that allow for the use of experimental therapies prior to approval and outside of the clinical trial setting, often in conjunction with patient advocacy groups and regulatory agencies. There could be potential disadvantages in allowing early access to a new cancer product, but a number of developers have also highlighted notable benefits derived from the process.


Puchase Reasons


To assess the view of expanded access programmes from the position of the physician community, FirstWord is polling oncologists based in the US and EU5. Specifically we are asking them...


  • How aware they are of expended access programmes?

  • What they perceive to be the key benefit of expanded access programmes?

  • What key concerns they have about expanded access programmes?

  • What issue with expanded access programmes needs resolving the most urgently?

  • Which stakeholder will play the most important role in driving wider adoption of expanded access programmes?
  • Table of Contents
    for Physician Views: Expanded access in cancer – how are oncologists utilising this opportunity? [Published by FirstWord Pharma]

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    117 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    SAVE 12% today! Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views: Expanded access in cancer – how are oncologists utilising this opportunity? [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...